Rhenman & Partners Asset Management AB Has $7.70 Million Stock Position in Biogen Inc. $BIIB

Rhenman & Partners Asset Management AB grew its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 358.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 55,000 shares of the biotechnology company’s stock after acquiring an additional 43,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $7,704,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of Biogen in the second quarter valued at approximately $284,358,000. Orion Porfolio Solutions LLC lifted its holdings in Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after purchasing an additional 509,809 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Biogen by 190.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock worth $78,415,000 after purchasing an additional 409,591 shares during the last quarter. Vanguard Group Inc. boosted its stake in Biogen by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock valued at $2,171,533,000 after purchasing an additional 257,812 shares during the period. Finally, Robeco Institutional Asset Management B.V. boosted its stake in Biogen by 49.5% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 671,054 shares of the biotechnology company’s stock valued at $94,001,000 after purchasing an additional 222,297 shares during the period. Institutional investors own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen will present new spinal muscular atrophy (SMA) data, including long‑term high‑dose nusinersen results and Phase 1b salanersen data as Phase 3 studies begin — news that supports the company’s SMA pipeline and could boost long‑term revenue potential if later trials read out favorably. Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
• Positive Sentiment: The New England Journal of Medicine published first data suggesting disease‑modifying potential for zorevunersen (Stoke Therapeutics collaboration) in Dravet syndrome, supporting the ongoing global Phase 3 EMPEROR study — a favorable scientific read that can increase confidence in Biogen’s partnered pipeline assets. The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
• Positive Sentiment: Proposed legislation (H.R. 7336, the ALS Better Care Act) would expand Medicare coverage and payments for ALS‑related services and incentivize clinical trial participation — a policy tailwind that could improve access and reimbursement for ALS therapies and indirectly benefit Biogen’s neurology franchise. New Bill: Representative Janice D. Schakowsky introduces H.R. 7336: ALS Better Care Act
• Neutral Sentiment: Analyst / investor pieces and fund letters have highlighted Biogen as an attractive long‑term holding (coverage in InsiderMonkey/Yahoo) — supportive for investor interest but not an immediate catalyst. What Makes Biogen (BIIB) an Attractive Long-Term Holding?
• Neutral Sentiment: Recent short‑interest reports show anomalous data (zero shares / NaN increases and a days‑to‑cover of 0.0), indicating reporting noise rather than a clear short‑selling pressure signal — treat these items as unreliable until clarified. (Internal short‑interest entries)
• Negative Sentiment: Despite positive pipeline and data releases, shares are down today — likely reflecting profit‑taking after recent gains, thin trading (volume below recent average), and market focus on near‑term revenue/guidance rather than later‑stage trial data. No new negative company‑specific regulatory or financial disclosures were reported in the entries provided.

Analysts Set New Price Targets

Several research firms have weighed in on BIIB. HC Wainwright increased their price objective on Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Wells Fargo & Company raised their price target on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. Tudor Pickering set a $201.00 price objective on shares of Biogen in a research note on Monday, February 9th. Truist Financial increased their target price on shares of Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a research report on Monday, February 9th. Finally, HSBC reaffirmed a “reduce” rating and set a $143.00 target price (down from $144.00) on shares of Biogen in a report on Wednesday, December 10th. Twelve analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $205.04.

Biogen Price Performance

Biogen stock opened at $184.87 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $202.41. The stock has a market capitalization of $27.13 billion, a P/E ratio of 20.98, a price-to-earnings-growth ratio of 1.47 and a beta of 0.15. The stock has a fifty day moving average of $183.08 and a 200-day moving average of $165.27.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen’s revenue was down 7.2% compared to the same quarter last year. During the same period last year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts expect that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.18% of the company’s stock.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.